BioChem Pharma Inc., of Laval, Quebec, said that results from five HIV trials suggest that Epivir (lamivudine) continues to have antiviral activity in HIV patients whose virus develops a mutation association with reduced susceptibility to nucleoside reverse transcriptase inhibitors (NRTIs). The results were presented at the third international workshop on HIV Drug Resistance and Treatment Strategies, in San Diego.